Kalaris Therapeutics, Inc. (KLRS)

Nasdaq; healthcare; SIC 2836, Biological Products, (No Diagnostic Substances); CIK 0001754068

Kalaris Therapeutics, Inc.

KLRS; healthcare

Grade	**E** — A B C D E weakest fifth of 371 graded peers percentile 84.6; sampling error 2.5 points; lower is stronger
Rank	314 of 371
Profitability	C — percentile 49.5
Solvency	C — percentile 46.5
Growth and financing	E — percentile 90.2
Reliability	0.87 AUC filers with $120M to $591M assets; 95% interval 0.83 to 0.90; 206 events, 2020 to 2025
Peer failure rate	1.03% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	$120M to $591M assets total assets $121.7M
Warnings	dilution not computable: degenerate inputs, fortress balance sheet
Inputs computable	7 of 14
Graded from	filings received through Mar 17, 2026 206 days before the rescan; latest periodic filing 10-Q received Aug 11, 2026
Last close	$2.50 2026-10-08; market equity $59.5M
Price used in grade	None

E, the bear

weakest fifth of its sector; letters are fifths of the 371 graded peers

Share price, twelve months to the rescan

split-adjusted close; the letter is fixed at the rescan that set it



Rescans on file: E from Aug 21, 2026

Letter at every rescan

Jan 21, 2012 to Oct 9, 2026; sector percentile, stronger toward the top; facts filed by each date only



Business, in the company's words

opening of Item 1 of the 10-K received Mar 17, 2026

We are a clinical stage biopharmaceutical company dedicated to the development and commercialization of treatments for prevalent retinal diseases with major unmet medical needs. We are developing TH103, a novel, clinical stage anti-vascular endothelial growth factor ("VEGF") drug, specifically engineered to achieve extended intraocular retention with enhanced VEGF inhibition in patients with exudative and/or neovascular retinal diseases. TH103 is a fully humanized recombinant fusion protein, functioning as a "decoy receptor" (a VEGF trap), leveraging salient molecular properties of the human body's native, highest affinity VEGF receptor 1.

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

The fourteen inputs

lower percentile is stronger; equal-weighted sleeves

Input	Percentile, 0 to 100	Value	Peer median	Percentile	Peers	Period end
Profitability, sleeve percentile 49.5						
Gross profitability		not computable	32.2%			one or more required annual facts are missing
Return on invested capital		not computable	9.3%			one or more required annual facts are missing
Accruals ratio		(7.9%)	(6.6%)	49.5	811	2025-12-31
Gross margin stability, five years		not computable	2.8 pts			five annual gross margins are required; found 0
Solvency, sleeve percentile 46.5						
Twelve-month failure probability		0.13%	0.07%	62.8	248	2026-06-30
Altman Z double-prime		0.97	(0.31)	32.7	756	2025-12-31
Net debt to EBITDA		not computable	1.82x			one or more required annual facts are missing
Interest coverage		(31.98x)	(4.51x)	78.8	81	2025-12-31
Current ratio		12.23x	2.96x	11.7	839	2025-12-31
Growth and financing, sleeve percentile 90.2						
Revenue growth, three-year compound		not computable	10.0%			four annual observations are required; found 0
Free cash flow growth, three-year compound		not computable	10.9%			four consecutive annual FCF observations are required; found 3
Reinvestment rate		not computable	37.1%			NOPAT must exceed $100,000
Asset growth, three years		(24.0%)	2.1%	87.8	704	2025-12-31
Net share issuance, one year		354.6%	2.5%	92.7	634	2026-03-10

Warnings

1 of 7 checks triggered; none of them enters the letter

Check	Measured
Dilution	split-adjusted year-over-year share growth is 354.6%

Among 371 peers

healthcare; letters are fifths of this list

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.



Composite score of every graded peer, smoothed; vertical rules are the letter band edges; stronger to the left.

Rank	Company	Percentile	Letter	Warnings
309	Karyopharm Therapeutics Inc. (KPTI)	83.2	E	dilution, distress, fortress balance sheet
310	Novavax Inc. (NVAX)	83.5	E	
311	Pyxis Oncology, Inc. (PYXS)	83.8	E	short runway, distress
312	Opko Health, Inc. (OPK)	84.1	E	fortress balance sheet
313	Amarin Corp. Plc\Uk (AMRN)	84.3	E	fortress balance sheet
314	Kalaris Therapeutics, Inc. (KLRS) <	84.6	E	dilution
315	Journey Medical Corp. (DERM)	84.9	E	
316	Amgen Inc. (AMGN)	85.1	E	
317	Organon & Co. (OGN)	85.4	E	
318	Sonoma Pharmaceuticals, Inc. (SNOA)	85.7	E	dilution, fortress balance sheet
319	Outset Medical, Inc. (OM)	85.9	E	dilution

What the price implies

at the 2026-10-08 close; none enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	(30.1%)	8.0%	25
Distance from 52-week high	(77.2%)	(31.4%)	9
EBIT to enterprise value	not computable	(1.5%)	
Free cash flow yield	(64.8%)	(1.0%)	8
Book value to price	0.97	0.28	86
Sales to price	not computable	0.31	
Composite equity issuance, five years	212.9%	20.3%	91
Relative strength against the sector, log excess return	(0.57)	(0.14)	25

Diagnostics

not in the grade

Measure	Value
Piotroski F-score None of 9, period end 2025-12-31	
Return on assets above zero	fail
Operating cash flow above zero	fail
Return on assets improved	fail
Operating cash flow exceeds net income	pass
Long-term leverage fell	fail
Current ratio improved	pass
No new shares issued	fail
Gross margin improved	fail

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Asset turnover improved	fail
Cash, filings, liquidity	
Cash and equivalents	$43.2M
Operating cash flow, four quarters	-$41.0M
Months of runway	12.6
Days since last periodic filing	59 (10-Q received Aug 11, 2026)
Median daily dollar volume, 63 sessions	$244,349

Sources

each row links to the filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	net income	us-gaap:NetIncomeLoss	-$43.4M	2025-12-31	2026-03-17	10-K	0001193125-26-110659
2	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$38.4M	2025-12-31	2026-03-17	10-K	0001193125-26-110659
3	assets	us-gaap:Assets	$121.7M	2025-12-31	2026-03-17	10-K	0001193125-26-110659
4	assets	us-gaap:Assets	$6.2M	2024-12-31	2026-03-17	10-K	0001193125-26-110659
5	current assets	us-gaap:AssetsCurrent	$118.8M	2025-12-31	2026-03-17	10-K	0001193125-26-110659
6	current liabilities	us-gaap:LiabilitiesCurrent	$9.7M	2025-12-31	2026-03-17	10-K	0001193125-26-110659
7	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	-$160.0M	2025-12-31	2026-03-17	10-K	0001193125-26-110659
8	operating income	us-gaap:OperatingIncomeLoss	-$46.2M	2025-12-31	2026-03-17	10-K	0001193125-26-110659
9	book equity	us-gaap:StockholdersEquity	$78.8M	2025-12-31	2026-03-17	10-K	0001193125-26-110659
10	liabilities	us-gaap:Liabilities	$42.9M	2025-12-31	2026-03-17	10-K	0001193125-26-110659
11	interest expense	us-gaap:InterestExpense	$1.4M	2025-12-31	2026-03-17	10-K	0001193125-26-110659
12	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$200,000	2025-12-31	2026-03-17	10-K	0001193125-26-110659
13	depreciation amortization	us-gaap:Depreciation	$13,000	2025-12-31	2026-03-17	10-K	0001193125-26-110659
14	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-$43.4M	2025-12-31	2026-03-17	10-K	0001193125-26-110659
15	income tax	us-gaap:IncomeTaxExpenseBenefit	$0	2025-12-31	2026-03-17	10-K	0001193125-26-110659
16	current assets	us-gaap:AssetsCurrent	$2.6M	2024-12-31	2026-03-17	10-K	0001193125-26-110659
17	current liabilities	us-gaap:LiabilitiesCurrent	$24.7M	2024-12-31	2026-03-17	10-K	0001193125-26-110659
18	assets	us-gaap:Assets	$190.8M	2023-12-31	2025-03-07	10-K	0000950170-25-035143
19	assets	us-gaap:Assets	$277.1M	2022-12-31	2024-03-15	10-K	0000950170-24-031879
20	shares outstanding	dei:EntityCommonStockSharesOutstanding	22,928,303	2026-03-10	2026-03-17	10-K	0001193125-26-110659
21	shares outstanding	dei:EntityCommonStockSharesOutstanding	5,043,357	2025-02-28	2025-03-07	10-K	0000950170-25-035143

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.